Evidence map›Paper›PMID 40197184›Full record

ArticleCurrent neuropharmacology2025

The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression.

Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi, Luca Montaguti, Giada Trovini, Daniela Donato, Giuseppe Costanzi, Donatella De Bernardini, Federica Catapano, Michele Surano and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marika AlborghettiDepartment of Neuroscience, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.
Luana LionettoClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Rome, Italy.
Ginevra LombardozziVilla Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Roma, Italy.
Luca MontagutiDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Giada TroviniVilla Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Roma, Italy.
Daniela DonatoVilla Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Roma, Italy.
Giuseppe CostanziClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Rome, Italy.
Donatella De BernardiniClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Rome, Italy.
Federica CatapanoDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Michele SuranoDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Ilaria PaganoDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Alessia CeccherelliDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Edoardo BianchiniDepartment of Neuroscience, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.
Giorgio Di LorenzoDepartment of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
Maurizio SimmacoDepartment of Neuroscience, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.
Giovanni MartinottiDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.
Georgios D KotzalidisVilla Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Roma, Italy.
Ferdinando NicolettiDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy.
Sergio De FilippisVilla Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Roma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectiveEsketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine's pharmacokinetic profile by inhibiting cytochrome-P

methodsSerum and salivary samples were collected from 53 patients receiving intranasal esketamine (56 mg) at baseline, after 20 min (roughly corresponding to T

resultsSalivary esketamine levels were several-fold higher than the corresponding serum levels at all time points, and showed high inter-individual variability. Serum 20-min post-esketamine levels and AUC

conclusionThe CY

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantKetamineAdministration, IntranasalAdultAgedDrug InteractionsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedSalivaAntidepressive AgentsEsketamineKetamineantidepressant drugscytochrome P<sub>450</sub> isoenzymes.depressionEsketaminepharmacokineticstreatment-resistant

Identifiers

PMID40197184
PMCPMC12307992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.